GlassScriptPhysician profile
Se Mo Suh
NPI 1003883240
$2,341.77
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $23.33 · 2021: $31.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $696.83 | 2019 | |
| Amarin Pharma, INC. | $369.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $357.96 | 2019 | |
| Abbvie INC. | $222.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.52 | 2019 | |
| Lilly USA, LLC | $135.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $133.93 | 2019 | |
| Merck Sharp & Dohme LLC | $119.95 | 2019 | |
| Glaxosmithkline, LLC. | $72.92 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $43.05 | 2019 | |
| Allergan, INC. | $23.33 | 2020 | |
| Astellas Pharma US INC | $12.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Se Mo Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.